TY - JOUR
T1 - Establishment of a Pediatric Ovarian and Testicular Cryopreservation Program for Malignant and Non-Malignant Conditions
T2 - The Mayo Clinic Experience
AU - Joshi, Vidhu B.
AU - Behl, Supriya
AU - Pittock, Siobhan T.
AU - Arndt, Carola A.S.
AU - Zhao, Yulian
AU - Khan, Zaraq
AU - Granberg, Candace F.
AU - Chattha, Asma
N1 - Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/10
Y1 - 2021/10
N2 - Study Objectives: To describe the structure of a pediatric fertility preservation (FP) program and to share safety and patient satisfaction data. Design: The FP program operates under prospective research protocols approved by the Mayo Clinic Institutional Review Board (IRB). Setting: The FP program is a multidisciplinary effort between pediatric gynecology, reproductive endocrinology, pediatric urology, pediatric surgery, and laboratory medicine. Participants: The FP program enrolls patients between 0-17 years of age who have been diagnosed with a fertility-threatening condition and/or are scheduled to undergo gonadotoxic treatment. Interventions: FP is offered in the form of ovarian tissue cryopreservation (OTC) and testicular (TTC) tissue cryopreservation. Main Outcome Measures: The outcome measures are the safety of the procedure and results of patient surveys conducted by phone using a standard list of questions to assess attitudes towards FP. Results: To date, we have enrolled 38 OTC and 37 TTC patients. The median age (range) of OTC and TTC patients was 11 years (0.83-17 years) and 10 years (0.92-17 years) at the time of enrollment, respectively. Childhood cancers currently represent 88% of the fertility-threatening diagnoses. Meanwhile, patients with non-malignant conditions include those with gender dysphoria, aplastic anemia, and Turner's syndrome. To date, no serious adverse events (SAEs) have been reported following surgery. According to n = 34 one-year follow-ups, 100% of parents felt that FP was a good decision. Conclusion: Consistent with the literature, our data suggests FP is safe and improves the quality of care provided to pediatric patients for their fertility-threatening diagnoses and/or treatments. Trial Registration: NCT02872532, NCT02646384.
AB - Study Objectives: To describe the structure of a pediatric fertility preservation (FP) program and to share safety and patient satisfaction data. Design: The FP program operates under prospective research protocols approved by the Mayo Clinic Institutional Review Board (IRB). Setting: The FP program is a multidisciplinary effort between pediatric gynecology, reproductive endocrinology, pediatric urology, pediatric surgery, and laboratory medicine. Participants: The FP program enrolls patients between 0-17 years of age who have been diagnosed with a fertility-threatening condition and/or are scheduled to undergo gonadotoxic treatment. Interventions: FP is offered in the form of ovarian tissue cryopreservation (OTC) and testicular (TTC) tissue cryopreservation. Main Outcome Measures: The outcome measures are the safety of the procedure and results of patient surveys conducted by phone using a standard list of questions to assess attitudes towards FP. Results: To date, we have enrolled 38 OTC and 37 TTC patients. The median age (range) of OTC and TTC patients was 11 years (0.83-17 years) and 10 years (0.92-17 years) at the time of enrollment, respectively. Childhood cancers currently represent 88% of the fertility-threatening diagnoses. Meanwhile, patients with non-malignant conditions include those with gender dysphoria, aplastic anemia, and Turner's syndrome. To date, no serious adverse events (SAEs) have been reported following surgery. According to n = 34 one-year follow-ups, 100% of parents felt that FP was a good decision. Conclusion: Consistent with the literature, our data suggests FP is safe and improves the quality of care provided to pediatric patients for their fertility-threatening diagnoses and/or treatments. Trial Registration: NCT02872532, NCT02646384.
KW - Cancer survivorship
KW - Childhood cancer
KW - Fertility preservation
KW - Infertility
KW - Oncofertility
KW - Transgender
UR - http://www.scopus.com/inward/record.url?scp=85107411616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107411616&partnerID=8YFLogxK
U2 - 10.1016/j.jpag.2021.04.006
DO - 10.1016/j.jpag.2021.04.006
M3 - Article
C2 - 33910089
AN - SCOPUS:85107411616
SN - 1083-3188
VL - 34
SP - 673
EP - 680
JO - Journal of Pediatric and Adolescent Gynecology
JF - Journal of Pediatric and Adolescent Gynecology
IS - 5
ER -